STOCKHOLM - Medivir AB (Nasdaq Stockholm: MVIR), a Swedish biopharmaceutical company, announced today that it will host a conference call to discuss recent developments in its ongoing phase 1b/2a study for advanced hepatocellular carcinoma (HCC), a primary liver cancer. The latest data from the study, involving the drug combination of fostrox and Lenvima®, was presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco on January 19.
The study data revealed that the combination treatment remains tolerable and continues to show improved clinical benefits as more data becomes available. Dr. Maria Reig from the Hospital Clinic of Barcelona presented the findings, which did not indicate any new, unexpected safety concerns.
Dr. Pia Baumann, Chief Medical Officer at Medivir, expressed confidence in the fostrox and Lenvima® combination as a potential treatment for advanced HCC patients. She noted that feedback from interactions with world-renowned experts at the symposium will inform the design of their upcoming study. This guidance is expected to be crucial for discussions with regulatory authorities concerning the final study design for a planned phase 2b study aimed at accelerated approval.
The conference call, which will provide an update on the study results and future plans, will feature Medivir's CEO Jens Lindberg, CMO Pia Baumann, and CSO Fredrik Öberg. Interested parties can access the webcast and teleconference details on Medivir's website.
Fostrox is a novel chemotherapy agent designed to selectively deliver the cell-killing compound to tumors, minimizing harm to normal cells. This prodrug is intended for oral administration and targets the liver directly. The drug has the potential to become the first liver-targeted, orally administered therapy for various liver cancers.
Primary liver cancer is a significant global health concern, with HCC being the most prevalent form. Despite available treatments, survival rates are low, and the disease's heterogeneity has hindered the success of targeted therapies.
Medivir specializes in developing innovative cancer treatments, particularly in areas where existing therapies are limited. The company's shares are publicly traded on the Nasdaq Stockholm exchange under the ticker MVIR.
The information is based on a press release statement
InvestingPro Insights
As Medivir AB continues to make strides in the development of treatments for hepatocellular carcinoma, it's essential for investors to understand the financial health and market performance of the company. Medivir is currently trading at a high earnings multiple, with a P/E ratio of 55.48, which adjusts to 32.79 for the last twelve months as of Q2 2023. This indicates a premium valuation that investors are willing to pay for the company's earnings potential. Despite not paying dividends, Medivir has maintained profitability over the last twelve months, showcasing the company's ability to generate earnings amidst its research and development efforts.
The company's stock is known for its low price volatility, which can be appealing for investors looking for more stability in their portfolio. This trait, combined with a robust revenue growth of 332.54% for the same period, suggests a strong upward trend in Medivir's financial performance. The InvestingPro Tips also highlight that with a PEG ratio of 0.1, the company's growth rate is not fully reflected in its share price, potentially offering an attractive opportunity for growth-focused investors.
For those interested in further insights and tips, subscribing to InvestingPro+ now comes with a special New Year sale offering a discount of up to 50%. Use coupon code SFY24 to get an additional 10% off a 2-year subscription, or SFY241 to get an additional 10% off a 1-year subscription. InvestingPro currently lists several additional tips that can provide deeper analysis and guidance for investors looking at Medivir as a potential addition to their portfolios.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.